Keyphrases
Thrombosis
100%
Platelets
92%
Immune Thrombocytopenia
72%
Platelet Activation
66%
Thrombocytopenia
53%
Vaccine Response
50%
United Kingdom
49%
Bleeding
47%
COVID-19
46%
Fostamatinib
38%
C-type Lectin-like Receptor 2
38%
Platelet Aggregation
36%
Ibrutinib
36%
Platelet Function
30%
Spleen Tyrosine Kinase
30%
Glycoprotein VI
29%
Platelet Factor 4
29%
Hemostasis
28%
Multicenter Observational Study
27%
Plasma Exchange
25%
Barbell
25%
Platelet Derivatives
25%
Imaging Flow Cytometry
25%
Vaccine-induced Immune Thrombotic Thrombocytopenia
25%
Sickle Cell Disease
25%
Ticagrelor
25%
Antiplatelet Drugs
24%
Spleen Tyrosine Kinase Inhibitor
24%
Anticoagulation
24%
Atherosclerotic Plaque
23%
Aspirin
23%
Healthy Donors
22%
Antithrombotic Effect
21%
Patient Serum
20%
Major Bleeding
19%
Hematology
18%
COVID-19 Vaccine
17%
Platelet Count
17%
Thrombotic Risk
17%
Thrombus Formation
17%
Thrombotic
16%
Venous Thrombosis
16%
Clinical Outcomes
15%
British Society
15%
Long-term Treatment
15%
Autoimmune Disease
15%
Thrombotic Thrombocytopenic Purpura
14%
Tyrosine Kinase
14%
Acalabrutinib
14%
Thrombopoietin Receptor Agonists (TPO-RAs)
14%
Medicine and Dentistry
Platelet
68%
Thrombosis
57%
COVID-19
56%
Thrombocyte Activation
42%
Antithrombotic
42%
Ibrutinib
41%
Bleeding
39%
Thrombotic Thrombocytopenic Purpura
38%
Antiplatelet
33%
Bruton Tyrosine Kinase Inhibitor
30%
Observational Study
29%
Clinician
27%
Plasma Exchange
25%
Idiopathic Thrombocytopenic Purpura
25%
Protein Kinase Syk
25%
Janus Kinase 1
25%
Protein Tyrosine Kinase
23%
Diseases
22%
Thrombocytopenia
21%
Anticoagulation
21%
Thrombocyte Aggregation
20%
Major Bleeding
18%
Blood Stasis
18%
Hematology
17%
Venous Thromboembolism
17%
Immunoglobulin
17%
Acalabrutinib
16%
Ciclonicate
15%
Ticagrelor
14%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Protein Kinase Syk Inhibitor
14%
Low Drug Dose
14%
Crizanlizumab
14%
Clinical Study
14%
Receptor
14%
Phlebothrombosis
14%
Caplacizumab
12%
Phosphotransferase Inhibitor
12%
Multiple Myeloma
12%
Monoclonal Gammopathy of Undetermined Significance
12%
Hematological Cancer
12%
Prn1008
12%
Cell Marker
12%
Bleeding Disorder
12%
Thrombocyte Transfusion
12%
Autoimmune Disease
12%
Glycoprotein VI
12%
Disease Course
12%
Thrombopoietin Receptor
12%
Patient with Sickle Cell Disease
12%
Pharmacology, Toxicology and Pharmaceutical Science
Idiopathic Thrombocytopenic Purpura
68%
Thrombosis
54%
Ibrutinib
41%
Bleeding
39%
Fostamatinib
38%
Anticoagulant Agent
37%
Bruton Tyrosine Kinase Inhibitor
32%
Protein Kinase Syk
28%
Janus Kinase 1
28%
Chemotherapy
25%
Thrombotic Thrombocytopenic Purpura
25%
Flow Cytometry
25%
Procoagulant
25%
Blood Stasis
25%
Antiplatelet
23%
Thrombocytopenia
22%
Protein Kinase Syk Inhibitor
21%
Ticagrelor
20%
Sickle Cell Anemia
19%
Antithrombocytic Agent
18%
Glycoprotein VI
17%
Acetylsalicylic Acid
17%
Thrombocyte Factor 4
17%
Diseases
17%
Observational Study
16%
Clinical Study
16%
Acalabrutinib
16%
Thrombus
16%
Thrombopoietin Receptor
15%
Normal Human
15%
Autoimmune Disease
15%
Crizanlizumab
14%
Receptor Agonist
14%
Vein Thrombosis
14%
Murine
14%
Antiphospholipid Syndrome
13%
Fludarabine
12%
Prothrombin Antibody
12%
Prn1008
12%
Caplacizumab
12%
Prothrombin
12%
Alemtuzumab
12%
Thiazole Orange
12%
Melphalan
12%
Phosphotransferase Inhibitor
12%
Graft Versus Host Reaction
12%
X Linked Agammaglobulinemia
12%
Protein Tyrosine Kinase
12%
Venous Thromboembolism
12%
SAD Mouse
12%